Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 6:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 71 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Open-label placebo pills Clear all
Completed Phase 2Phase 3 Interventional Results available

Selinexor in Advanced Liposarcoma

NCT02606461
View directory record Official record
Conditions
Dedifferentiated Liposarcoma
Interventions
Selinexor, Placebo
Drug
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
12 Years and older
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
26
States / cities
Los Angeles, California • Santa Monica, California • Stanford, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2023 · Synced Sep 23, 2026, 6:21 AM EDT
Not listed Phase 4 Interventional

Sublingual Apomorphine in Refractory Restless Legs Syndrome

NCT05529095
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Apomorphine Sublingual Film, Placebo
Drug
Lead sponsor
William Ondo, MD
Other
Eligibility
21 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 5, 2022 · Synced Sep 23, 2026, 6:21 AM EDT
Completed Not applicable Interventional Results available

Eplerenone in HIV Associated Abdominal Fat Accumulation

NCT01405456
View directory record Official record
Conditions
HIV
Interventions
Eplerenone and lifestyle, placebo and lifestyle
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
30 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Sep 23, 2026, 6:21 AM EDT
Completed Phase 4 Interventional Results available

Quetiapine Augmentation for Treatment-resistant PTSD

NCT00292370
View directory record Official record
Conditions
Combat Disorders, Stress Disorders, Post-Traumatic
Interventions
Open Label (OL) Paroxetine, Placebo, Quetiapine
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 75 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Sep 23, 2026, 6:21 AM EDT
Completed Not applicable Interventional

Harnessing Placebo Effects in Methadone Treatment

NCT02941809
View directory record Official record
Conditions
Opioid-use Disorder, Opioid-Related Disorders
Interventions
Open-Label Placebo (OLP)
Behavioral
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Sep 23, 2026, 6:21 AM EDT
Completed Phase 3 Interventional

A Study of Zonisamide to Prevent Olanzapine-Associated Weight Gain

NCT00363376
View directory record Official record
Conditions
Weight Gain
Interventions
Zonisamide, olanzapine, Sugar Pill (placebo)
Drug
Lead sponsor
Lindner Center of HOPE
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Mason, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 12, 2012 · Synced Sep 23, 2026, 6:21 AM EDT
Completed Not applicable Interventional

Open-Label Placebos to Treat Fatigue in Multiple Sclerosis

NCT04002102
View directory record Official record
Conditions
Multiple Sclerosis, Fatigue
Interventions
OLP treatment, Usual care, Expectancy Group
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 31, 2022 · Synced Sep 23, 2026, 6:21 AM EDT
Completed Phase 4 Interventional Results available

Neural Mechanisms of Monoaminergic Engagement in Late-life Depression Treatment Response (NEMO)

NCT03128021
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Escitalopram Pill, Placebo, Levomilnacipran Pill
Drug · Other
Lead sponsor
Howard Aizenstein
Other
Eligibility
60 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 9, 2025 · Synced Sep 23, 2026, 6:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Gut-Cued Eating on BMI and Efficacy of Open-Label Placebo to Augment Weight Loss

NCT03850990
View directory record Official record
Conditions
Eating Behavior, Obesity, Body Weight, Hunger
Interventions
Placebo pill and no placebo pill
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 60 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 3, 2021 · Synced Sep 23, 2026, 6:21 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Use of an Herbal Preparation to Prevent and Dissolve Kidney Stones

NCT00381849
View directory record Official record
Conditions
Cystinuria, Nephrolithiasis, Calcium Oxalate
Interventions
Cystone, Sugar Pill (Placebo)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 100 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Sep 23, 2026, 6:21 AM EDT
Completed Phase 4 Interventional Results available

Combining Medications to Enhance Depression Outcomes

NCT00590863
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
SSRI + placebo, Escitalopram + Bupropion SR, Venlafaxine XR + Mirtazapine
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 75 Years
Enrollment
665 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
15
States / cities
Tuscaloosa, Alabama • Harbor City, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2014 · Synced Sep 23, 2026, 6:21 AM EDT
Terminated Phase 4 Interventional Results available

A Study of Creon (Pancrelipase) in Resected and Non-resected Pancreatic Cancer Participants With Exocrine Pancreatic Insufficiency (EPI)

NCT03859869
View directory record Official record
Conditions
Exocrine Pancreatic Insufficiency (EPI)
Interventions
Pancrelipase, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
21 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
33
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2023 · Synced Sep 23, 2026, 6:21 AM EDT
Completed Phase 4 Interventional Results available

Brain Aging and Treatment Response in Geriatric Depression

NCT01902004
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI), Depression
Interventions
Escitalopram, Memantine, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
60 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2019 · Synced Sep 23, 2026, 6:21 AM EDT
Completed Not applicable Interventional Results available

A Trial of SAMe for Treatment-Resistant Bipolar Depression

NCT00762268
View directory record Official record
Conditions
Bipolar Disorder, Depression, Bipolar Depression
Interventions
SAMe, Placebo
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Sep 23, 2026, 6:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Effect of Mucinex® 1200 mg on Mucociliary and Cough Clearance From the Human Lung

NCT00902707
View directory record Official record
Conditions
Mucociliary Clearance
Interventions
Mucinex 1200mg, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 10, 2012 · Synced Sep 23, 2026, 6:21 AM EDT
Completed Phase 2 Interventional Results available

Exenatide in Extreme Pediatric Obesity

NCT01237197
View directory record Official record
Conditions
Obesity
Interventions
Exenatide, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
12 Years to 19 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Minneapolis, Minnesota • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 11, 2014 · Synced Sep 23, 2026, 6:21 AM EDT
Recruiting Not applicable Interventional

Placebo Impacts Sleep and Pain Modulation in Chronic Pain

NCT06225817
View directory record Official record
Conditions
Chronic Pain, Headache
Interventions
Open-label placebo pills
Dietary Supplement
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 88 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 23, 2026, 6:21 AM EDT
Active, not recruiting Phase 2 Interventional

Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE)

NCT04239625
View directory record Official record
Conditions
Stargardt Disease, Stargardt Macular Degeneration, Stargardt Macular Dystrophy, Autosomal Recessive Stargardt Disease 1 (ABCA4-related)
Interventions
ALK-001
Drug
Lead sponsor
Alkeus Pharmaceuticals, Inc.
Industry
Eligibility
8 Years to 70 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
8
States / cities
Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2026 · Synced Sep 23, 2026, 6:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

VA106483 Dose Response Study in Elderly Males

NCT00922740
View directory record Official record
Conditions
Nocturia
Interventions
VA106483, Placebo
Drug
Lead sponsor
Vantia Ltd
Industry
Eligibility
65 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Sep 23, 2026, 6:21 AM EDT
Completed Phase 2 Interventional Results available

Pilot Study to Evaluate Escitalopram in Obsessive-compulsive Disorder

NCT00215137
View directory record Official record
Conditions
OCD
Interventions
escitalopram, Placebo ( sugar pill)
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 22, 2014 · Synced Sep 23, 2026, 6:21 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

RESTOR: PK/PD mTORi Inhibition in Older Adults

NCT06658093
View directory record Official record
Conditions
Aging
Interventions
Rapamycin, Everolimus, Placebo
Drug · Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
65 Years to 90 Years
Enrollment
194 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Sep 23, 2026, 6:21 AM EDT
Active, not recruiting Not applicable Interventional

Mindfulness And Placebo for Pain (MAPP) Study

NCT06720909
View directory record Official record
Conditions
Chronic Pain
Interventions
Mindfulness-Based Stress Reduction (MBSR), Open-Label Placebo (OLP), MBSR+OLP
Behavioral · Other
Lead sponsor
Arizona State University
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 23, 2026, 6:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

VA106483 Dose Response in Females

NCT01171391
View directory record Official record
Conditions
Nocturia
Interventions
VA106483, Placebo
Drug · Other
Lead sponsor
Vantia Ltd
Industry
Eligibility
40 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 30, 2010 · Synced Sep 23, 2026, 6:21 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Bringing Simple Urge Incontinence Diagnosis & Treatment to Providers (BRIDGES)

NCT00862745
View directory record Official record
Conditions
Urge Urinary Incontinence, Overactive Bladder
Interventions
Fesoterodine, Matching Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Female only
Enrollment
645 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
13
States / cities
Birmingham, Alabama • San Diego, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2011 · Synced Sep 23, 2026, 6:21 AM EDT